Literature DB >> 25849033

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

Marwan N Sabbagh1, Kewei Chen2, Joseph Rogers3, Adam S Fleisher4, Carolyn Liebsack5, Dan Bandy4, Christine Belden5, Hillary Protas4, Pradeep Thiyyagura4, Xiaofen Liu4, Auttawut Roontiva4, Ji Luo4, Sandra Jacobson5, Michael Malek-Ahmadi5, Jessica Powell5, Eric M Reiman6.   

Abstract

INTRODUCTION: Down syndrome (DS) is associated with amyloid b (Ab) deposition.
METHODS: We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2), and 9 normal controls (NCs).
RESULTS: There were significant group differences in mean standard uptake value ratios (SUVRs) for florbetapir with DS/AD1 having the highest, followed by DS/AD2, followed by NC. For [18F]-fluorodeoxyglucose positron emission tomography, posterior cingulate rCMRgl in DS/AD1 was significantly reduced compared with DS/AD2 and NC. For volumetric magnetic resonance imaging (vMRI), hippocampal volumes were significantly reduced for the DS/AD1 compared with DS/AD2 and NC. Age-related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs. DISCUSSION: DS is associated with fibrillar Ab, rCMRgl, and rGMV alterations in the dementia stage and before the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia; Down syndrome; FDG-PET; Florbetapir; Imaging; PET

Mesh:

Substances:

Year:  2015        PMID: 25849033      PMCID: PMC4543530          DOI: 10.1016/j.jalz.2015.01.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  40 in total

Review 1.  Voxel-based morphometry--the methods.

Authors:  J Ashburner; K J Friston
Journal:  Neuroimage       Date:  2000-06       Impact factor: 6.556

2.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Authors:  Gene E Alexander; Kewei Chen; Pietro Pietrini; Stanley I Rapoport; Eric M Reiman
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

3.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

4.  Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome.

Authors:  Stefan J Teipel; Mark B Schapiro; Gene E Alexander; Jack S Krasuski; Barry Horwitz; Christian Hoehne; Hans-Jürgen Möller; Stanley I Rapoport; Harald Hampel
Journal:  Am J Psychiatry       Date:  2003-10       Impact factor: 18.112

5.  A voxel-based morphometric study of nondemented adults with Down Syndrome.

Authors:  Nathan S White; Michael T Alkire; Richard J Haier
Journal:  Neuroimage       Date:  2003-09       Impact factor: 6.556

6.  Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

Authors:  Marwan N Sabbagh; Adam Fleisher; Kewei Chen; Joseph Rogers; Camryn Berk; Eric Reiman; Michael Pontecorvo; Mark Mintun; Daniel Skovronsky; Sandra A Jacobson; Lucia I Sue; Carolyn Liebsack; Albert S Charney; Lauren Cole; Christine Belden; Thomas G Beach
Journal:  Arch Neurol       Date:  2011-11

7.  Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease.

Authors:  Jack S Krasuski; Gene E Alexander; Barry Horwitz; Stanley I Rapoport; Mark B Schapiro
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

Review 8.  Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

Authors:  Richard J Caselli; Eric M Reiman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

10.  Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.

Authors:  Stefan J Teipel; Gene E Alexander; Marc B Schapiro; Hans-Jürgen Möller; Stanley I Rapoport; Harald Hampel
Journal:  Brain       Date:  2004-02-25       Impact factor: 13.501

View more
  32 in total

1.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

Review 2.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

3.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

Review 4.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

5.  Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Authors:  Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

7.  Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome.

Authors:  Natalie D DiProspero; David B Keator; Michael Phelan; Theo G M van Erp; Eric Doran; David K Powell; Kathryn L Van Pelt; Frederick A Schmitt; Elizabeth Head; Ira T Lott; Michael A Yassa
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 8.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

9.  High-resolution functional connectivity of the default mode network in young adults with down syndrome.

Authors:  Katherine A Koenig; Lynn M Bekris; Stephen Ruedrich; Grace E Weber; Maria Khrestian; Se-Hong Oh; Sanghoon Kim; Z Irene Wang; James B Leverenz
Journal:  Brain Imaging Behav       Date:  2020-10-18       Impact factor: 3.224

10.  The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Authors:  Michael S Rafii; Hannah Wishnek; James B Brewer; Michael C Donohue; Seth Ness; William C Mobley; Paul S Aisen; Robert A Rissman
Journal:  Front Behav Neurosci       Date:  2015-09-14       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.